Physician profile
Roberto Miranda
NPI 1134163892
$2,103.16
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $806 · 2020: $665 · 2022: $145 · 2023: $468 · 2024: $18.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $487.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $486.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $260.20 | 2019-2023 | Farxiga, Breztri |
| Glaxosmithkline, LLC. | $192.96 | 2019-2023 | Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $179.45 | 2020-2023 | Rybelsus, Ozempic |
| Amgen INC. | $150.92 | 2019-2023 | Repatha, Otezla |
| Boston Scientific Corporation | $133.95 | 2019 | |
| Amarin Pharma, INC. | $127.38 | 2019-2020 | |
| Abbvie INC. | $100.81 | 2019-2023 | |
| Astellas Pharma US INC | $94.55 | 2019-2023 | Veozah |
| Pfizer INC. | $93.50 | 2019-2023 | |
| Arbor Pharmaceuticals, INC. | $89.84 | 2019 | |
| Eisai INC. | $83.76 | 2020 | |
| Novartis Pharmaceuticals Corporation | $81.36 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $67.61 | 2019-2023 | |
| Lilly USA, LLC | $49.61 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.26 | 2020-2024 | Trulance, Xifaxan |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $44.39 | 2023 | Lyvispah |
| Janssen Pharmaceuticals, INC | $41.35 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $33.54 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.69 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $30.28 | 2022 | |
| Allergan, INC. | $24.14 | 2020 | |
| Horizon Therapeutics Plc | $22.12 | 2019 | |
| Vital Connect, INC | $18.94 | 2023 | Vitalpatch Rtm |
| Genentech USA, INC. | $18.22 | 2019 | |
| Xeris Pharmaceuticals, INC. | $16.17 | 2023 | Gvoke Hypopen |
| Kowa Pharmaceuticals America, INC. | $14.75 | 2020 | |
| Dexcom, INC. | $14.50 | 2023 | Dexcom G6 Transmitter |
| Mylan Specialty L.P. | $13.65 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.18 | 2022 | |
| Esperion Therapeutics, INC. | $12.08 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Miranda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.